Key result
BMP pathway modulation emerges as a therapeutic strategy for pathologies driven by dysregulated Smad signaling.
Answers are grounded in this paper and cite their sources.
Bone morphogenetic proteins (BMPs) constitute the largest subdivision of the transforming growth factor (TGF)-β family of ligands and exert most of their effects through the canonical effectors Smad1, 5, and 8. Appropriate regulation of BMP signaling is critical for the development and homeostasis of numerous human organ systems. Aberrations in BMP pathways or their regulation are increasingly associated with diverse human pathologies, and there is an urgent and growing need to develop effective approaches to modulate BMP signaling in the clinic. In this review, we provide a wide perspective on diseases and/or conditions associated with dysregulated BMP signal transduction, outline the current strategies available to modulate BMP pathways, highlight emerging second-generation technologies, and postulate prospective avenues for future investigation.
No takes yet. Share an insight, caveat, or question.
Lowery et al. (2017) conducted a review in Diseases and conditions associated with dysregulated BMP signal transduction. Bone morphogenetic protein (BMP)-based therapeutic approaches was evaluated. Bone morphogenetic protein (BMP) pathway modulation strategies and second-generation technologies are reviewed for treating pathologies driven by dysregulated Smad1, 5, and 8 signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: